# PharmaDiagnostics NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmadiagnostics

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.pharmadiagnostics.com
- Total disclosed funding: $3.7M
- Latest round: Series B (Oct 12, 2009)
- Investors on record: 3

## About

PharmaDiagnostics NV is a Belgium-based company focused on delivering advanced diagnostic solutions to enhance healthcare outcomes for medical professionals and institutions.Founded in 2007 in Belgium, PharmaDiagnostics NV specializes in innovative diagnostic services. The company has not reported any changes in its operations or business strategy. The company has successfully raised a total of EUR 2.50 mn through its latest funding round, the Series B, led by Capital-E Partners. Other investors in this round included Allegro Investment Fund and PMV - ParticipatieMaatschappij Vlaanderen NV.PharmaDiagnostics NV specializes in providing innovative diagnostic solutions aimed at enhancing healthcare outcomes. The core offerings include diagnostic tests and services designed for healthcare providers to accurately diagnose medical conditions. These products utilize advanced technology to ensure precision and reliability, primarily serving laboratories, hospitals, and clinics. The end users are healthcare professionals requiring accurate and timely diagnostic information to inform treatment decisions, with a market focus on North America, Europe, and parts of Asia.In the most recent year, 2016, PharmaDiagnostics NV reported a revenue of EUR 7,195.50 mn. The company generated revenue through direct sales to healthcare institutions and partnerships with diagnostic laboratories, involving bulk orders of diagnostic kits and related services. The ongoing contracts for supply and support services further contribute to the company’s revenue, maintaining strong relationships with its customers across various regions.PharmaDiagnostics NV has announced an exit strategy, indicating plans for potential divestment. While specific upcoming products and geographic expansion plans have not been detailed, the utilization of recent funding will support strategic initiatives that align with its growth objectives.

## Funding rounds

- Series B, Oct 12, 2009, $3.7M — Capital-E Partners, PMV, Allegro Investment Fund

## Investors

- Capital-E Partners (https://capitalatlas.ai/funds/capital-e-partners) — Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Series B
- Allegro Investment Fund — Series B